Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists

International Journal of Obesity

Volumn 23, Issue 4, 1999, Pages 425-431

  Scislowski, Piotr W D ^a   Tozzo, E ^a   Zhang, Y ^a   Phaneuf, S ^a   Prevelige, R ^a   Cincotta, A H ^a  

^a Ergo Science Corp   (United States)

Author keywords

Bromocriptine; Diabetes; Dopamine; Gluconeogenesis; Lipogenesis; Lipolysis; Obesity; SKF38393

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BROMOCRIPTINE; CORTICOSTERONE; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME; FATTY ACID; GLUCOSE; GLYCOGEN; PRASTERONE SULFATE; THYROXINE; UNCLASSIFIED DRUG; XYLULOSE; XYLULOSE 5 PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCHEMISTRY; BODY FAT; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DIABETES MELLITUS; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FEMALE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPHAGIA; INTRAPERITONEAL DRUG ADMINISTRATION; LIPOGENESIS; LIPOLYSIS; LIVER; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RESPIRATORY QUOTIENT; THYROXINE BLOOD LEVEL;

ANIMALIA;

EID: 0032913283     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800893     Document Type: Article

References (39)

1. 2 consumption and early detection of ob/ob genotype in mice. Am J Physiol 1974; 227: 912-915.
2. 2 Godbole VY, Grundleger ML, Thenen SW. Early development of lipogenesis in genetically obese (ob/ob) mice. Am J Physiol 1980; 239: E265-E268.
3. 3 Oltmans GA. Norepinephrine and dopamine levels in hypothalamic nuclei of genetically obese mouse (ob/ob). Brain Res 1983; 273: 369-373.
4. 4 Cincotta AH, Tozzo E, Scislowski PWD, Bromocriptine/SKF 38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61: 951-956.
5. 5 Nepokroeff CM, Lakshmanan MR, Porter JW. Fatty acid synthetase from rat liver. Methods Enzymol 1975; 35: 37-44.
6. 6 Spydevold SO, Greenbaum AL, Baquer NZ, McLean P. Adaptive responses of enzymes of carbohydrate and lipid metabolism to dietary alternation in genetically obese Zucker rats (fa/fa). Eur J Biochem 1978; 89: 329-339.
7. 7 Ballard FJ, Hanson RW. Phosphoenolpyruvate carboxykinase and pyruvate carboxylase in developing rat liver. Biochem J 1967; 104: 86-871.
8. 8 Burchell A, Hume R, Burchell B. A new microtechnique for the analysis of the human hepatic microsomal glucose-6-phosphate system. Clin Chim Acta 1988; 173: 183-191.
9. 9 Casazza JP, Veech RL. The interdependence of glycolytic and pentose cycle intermediates in ad libitum fed rats. J Biol Chem 1986; 261: 690-698.
10. 10 Hietanen E, Greenwood MR. A comparison of lipoprotein lipase activity and adipocyte differentiation in growing male rats. J Lipid Res 1977; 18: 480-490.
11. 11 Belfrage P, Vaughan M. Simple liquid liquid partition system for isolation of labeled oleic acid from mixtures with glycerides. J Lipid Res 1969; 10: 341-344.
12. 12 Honnor RC, Dhillon GS, Londos C. cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators. J Biol Chem 1985; 260: 15130-15138.
13. 13 Londos C, Honnor RC, Dhillon GS. cAMP-dependent protein kinase and lipolysis in rat adipocytes. III. Multiple modes of insulin regulation of lipolysis and regulation of insulin responses by adenylate cyclase regulators. J Biol Chem 1985; 260: 15139-15145.
14. 14 Tozzo E, Gnudi L, Kahn BB. Ameliorations of insulin resistance in streptozotocin diabetic mice by transgenic overexpression of GLUT 4 driven by an adipose-specific promoter. Endocrinology 1997; 138: 1604-1611.
15. 15 Lavau M, Susini C, Knittle J, Blanchet-Hirst S, Greenwood MR. A reliable photomicrographic method to determining fat cell size and number: application to dietary obesity. Proc Soc Exp Biol Med 1977; 158: 251-256.
16. 16 Jackson DM, Ross SB, Hashizume M. Dopamine-mediated behaviours produced in naïve mice by bromocriptine plus SKF 38393. J Pharma Pharmacol 1988; 40: 221-223.
17. 17 Cincotta AH, MacEachern TA, Meier A. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993; 264: E285-E293.
18. 18 Hwa JJ, Fawzi AB, Graziano MP, Ghibaudi L, Williams P, vanHeek M, Davis H, Rudinski M, Sybertz E, Strader CD. Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am J Physiol 1997; 272: R1204-R1209.
19. 19 Schutz Y. The basis of direct and indirect calorimetry and their potentials. Diabetes/Metab Rev 1995; 11: 383-408.
20. 20 Elia M, Livesey G. Theory and validity of indirect calorimetry during net lipid synthesis. Am J Clin Nutr 1988; 47: 591-607.
21. 21 Erminio C, Greengard P. In Goldstein M, Lieberman A, Calne BB, Thorner MO (eds). Advances in Biochemical Psychopharmacology 1980 Vol. 23 Raven: New York, pp 41-62
22. 22 Cincotta AH, Meier AH. Bromocrriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 1995; 44: 1349-1355.
23. 23 Eckel RH. Lipoprotein lipase. A multi functional enzyme relevant to common metabolic diseases. N Engl J Med 1989; 320: 1060-1068.
24. 24 Nishimura M, Fedorov S, Uyeda K. Glucose-stimulated synthesis of fructose 2,6 biphosphate in rat liver. Dephosphorylation of fructose 6 phosphate, 2 kinase fructose 2,6 biphosphatease and activation by a sugar phosphate. J Biol Chem 1994; 269: 26100-26106.
25. 25 Liu YQ, Uyeda K. A mechanism for fatty acid inhibition of glucose utilization in liver. Role of xylulose 5 phosphate. J Biol Chem 1996; 271: 8824-8830.
26. 26 Cadefau J, Bollen M, Stalmans W. Glucose-induced glycogenesis in the liver involves the glucose-6-phosphate-dependent dephosphorylation of glycogen synthase. Biochem J 1977; 322: 745-750.
27. 27 Peret J, Chanez M, Bois B. Schedule of protein ingestion and circadian variations of glycogen phosphorylase, glycogen synthetase and phosphoenol pyruvate carboxykinase in rat liver. J Nutr 1978; 108: 265-272.
28. 28 Lea-Currie YR, Wu SM, McIntosh MK. Effects of acute administration of dehydroepiandrosterone sulfate on adipose tissue mass and cellularity in male rats. Int J Obes 1997; 21: 147-154.
29. 29 Feldkricher KM, Mistry AM, Romsos DR. Adrenalectomy reverses pre-existing obesity in adult genetically obese (ob/ob) mice. Int J Obes 1996; 20: 232-235.
30. 30 Chen HL, Romsos DR. Dexamethasone rapidly increases hypothalamic neuropeptide Y secretion in adrenalectomized ob/ob mice. Am J Physiol 1996; 271: E151-E158.
31. 31 Thomas SA, Palmiter RD. Thermoregulatory and metabolic phenotypes of mice lacking noradrenaline and adrenaline. Nature 1997; 387: 94-97.
32. 32 Stanley BG, Magdalin W, Seirafi A, Thomas WJ, Leibowitz SF. The perifomical area: the major focus of (a) patchily distributed hypothalamic neuropeptide Y-sensitive feeding system(s). Brain Res 1993; 604: 304-317.
33. 1 agonist suppresses overexpression of hypothalamic NPY mRNA, hyperglycemia and body weight gain in female ob/ob mice. Soc Neurosci (Abstract) 1997; 23: 659.13.
34. 34 Bina K, Hodge S. Treatment with dopaminergic D1/D2 agonists in the ob/ob mouse decreases hyperphagia, hyperglycemia, obesity and NPY immunoreactivity in discrete hypothalamic nuclei. Diabetes 1997; 46(Suppl. 1): 228A.
35. 35 Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Intracerebrovenricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994; 43: 764-769.
36. 36 Luo S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology 1998; 68: 1-10.
37. 37 Nonogaki K, Iguchi A. Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 1997; 60: 797-807.
38. 38 Luo S, Hodge S, Luo J, Castro S, Cincotta AH. The anti-diabetic effects of bromocriptine are effectively mediated via intracerebroventricular administration. Diabetes 1998; 47(Suppl. 1): A78.
39. 39 Cincotta AH, Scislowski P, Phaneuf S, Prevelige R, Joslin J. Dopamine agonist treatment ameliorates the obese hyperleptinemic condition in lethal yellow (Ay/a) mice. Diabetes 1998; 47(Suppl. 1): A318.